Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio

Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.

EraseDementia_1200x675
• Source: Shutterstock

AstraZeneca PLC and Eli Lilly & Co. have agreed to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease. The product was discovered in AstraZeneca's Medimmune laboratories.

[Sidebar#SC097815]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip